Compare AVO & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVO | KALV |
|---|---|---|
| Founded | 1983 | N/A |
| Country | United States | United States |
| Employees | 3800 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2020 | 2014 |
| Metric | AVO | KALV |
|---|---|---|
| Price | $14.38 | $19.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $17.00 | ★ $32.60 |
| AVG Volume (30 Days) | 844.4K | ★ 1.1M |
| Earning Date | 03-12-2026 | 05-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.92 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,391,200,000.00 | $50,000,000.00 |
| Revenue This Year | N/A | $187.19 |
| Revenue Next Year | $2.35 | $54.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.68 | ★ 495.66 |
| 52 Week Low | $9.60 | $9.83 |
| 52 Week High | $15.02 | $21.31 |
| Indicator | AVO | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 65.02 |
| Support Level | $11.60 | $14.66 |
| Resistance Level | $15.02 | N/A |
| Average True Range (ATR) | 0.52 | 1.29 |
| MACD | 0.18 | 0.30 |
| Stochastic Oscillator | 97.78 | 77.39 |
Mission Produce Inc produces, packs, and distributes mainly Hass avocados to retail, wholesale, and food service customers, offering pre-ripe and ripened fruit tailored to customer specifications through its network of ripening facilities. The Company operates through three segments: Marketing & Distribution, which sources and distributes fruit globally and generates the majority of revenue; International Farming, which owns and operates avocado orchards and supplies fruit mainly to Marketing & Distribution, with operations principally in Peru and Guatemala; and Blueberries, which farms blueberries sold under an exclusive marketing agreement. The Company's operations span Peru, the United States, Guatemala, Mexico, Europe, and Canada.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.